BindingDB Data by Journal
PMID
Data
Article Title
Citation
Organization
Download Data
Novel TYK2 Inhibitors for Treating Autoimmune and Inflammatory Diseases.
ACS Med Chem Lett 16: 8-9 (0)
Smith, Gambrell & Russell
Novel Bicyclic Heterocyclic Compounds as CD73 Inhibitors for Treating Cancer.
ACS Med Chem Lett 16: 10-11 (0)
Smith, Gambrell & Russell
Pyrrolopyrazine Compounds as ERK5 Inhibitors for Treating Cancer.
ACS Med Chem Lett 16: 16-17 (0)
Smith, Gambrell & Russell
Novel 3-Pyrrolidineindole Derivatives as Serotonergic Psychedelic Agents for Treating Psychosis and Mental Illnesses Such as Depression and Post-Traumatic Stress Disorder.
ACS Med Chem Lett 16: 18-19 (0)
Smith, Gambrell & Russell
Novel Approaches in Biotechnology: Microbial Genetic Modifications and Metabolic Disease Therapies.
ACS Med Chem Lett 16: 23-25 (0)
Usona Institute
Optimizing Linezolid: Transforming It into a Selective MAO-B Inhibitor via a Toxicity-to-Activity Optimization Approach.
ACS Med Chem Lett 16: 40-50 (0)
R. C. Patel Institute of Pharmaceutical Education and Research
Sialyl Lewisx Glycomimetics as E- and P-Selectin Antagonists Targeting Hyperinflammation.
ACS Med Chem Lett 16: 64-71 (0)
University of Ottawa
Discovery of a Potent Triazole-Based Reversible Targeted Covalent Inhibitor of Cruzipain.
ACS Med Chem Lett 16: 72-79 (0)
Universidad Nacional de Cordoba (FCQ-UNC)
Structure-Based Design of Novel TLR7/8 Agonist Payloads Enabling an Immunomodulatory Conjugate Approach.
ACS Med Chem Lett 16: 80-88 (0)
Bristol Myers Squibb Research & Development
Development of a Buchwald-Hartwig Amination for an Accelerated Library Synthesis of Cereblon Binders.
ACS Med Chem Lett 16: 89-95 (0)
Bristol Myers Squibb
Second-Generation Cap Analogue Prodrugs for Targeting Aberrant Eukaryotic Translation Initiation Factor 4E Activity in Cancer.
ACS Med Chem Lett 16: 96-100 (0)
University of Michigan
Discovery of Novel Pyrimidine Derivatives as Human Pin1 Covalent Inhibitors.
ACS Med Chem Lett 16: 101-108 (0)
Chinese Academy of Medical Sciences and Peking Union Medical College
Expanding the Chemical Space of Reverse Fosmidomycin Analogs.
ACS Med Chem Lett 16: 136-143 (0)
Heinrich Heine University Dusseldorf
Synthesis and Biological Evaluation of 5'-Deoxy-adenosine Derivatives as A3 Adenosine Receptor Ligands.
ACS Med Chem Lett 16: 149-156 (0)
Seoul National University
Tetrazole Is a Novel Zinc Binder Chemotype for Carbonic Anhydrase Inhibition.
ACS Med Chem Lett 16: 163-166 (0)
University of Florence
Discovery of a Phosphodiesterase 7A Inhibitor of High Isozyme Selectivity Exhibiting In Vivo Anti-Osteoporotic Effects.
ACS Med Chem Lett 16: 167-173 (0)
Central Pharmaceutical Research Institute
Cyclic Peptides Targeting Granzyme B: Potential Applications as PET Imaging Agents.
ACS Med Chem Lett 16: 180-181 (0)
Emory University
Imaging Alpha-synuclein with Novel 5H-Imidazo[1,5-b][1,2,4]triazole Radioligands for the Diagnosis of Parkinson's Disease.
ACS Med Chem Lett 16: 182-183 (0)
Emory University
Novel Heterocyclic Piperazine Amide Derivatives as Alpha-synuclein PET Ligands for Diagnosis of Parkinson's Disease.
ACS Med Chem Lett 16: 184-185 (0)
Emory University
Novel Imidazo[4,5-c]pyridine Compounds as TLR7 Agonists for Treating Cancer.
ACS Med Chem Lett 16: 188-189 (0)
Smith Gambrell & Russell LLP
Novel 3-Cycloaminoindole Compounds as Serotonergic Psychedelic Agents for Treating Psychosis, Mental Illness, and CNS Disorders.
ACS Med Chem Lett 16: 190-191 (0)
Smith, Gambrell & Russell
Novel 6-Substituted-3-Phenylisoindolin-1-ones as Cbl-B Inhibitors for Treating Cancer.
ACS Med Chem Lett 16: 194-195 (0)
Smith, Gambrell & Russell
Novel Indoline Derivatives as Serotonergic Psychedelic Agents for Treating Psychosis, Mental Illness and CNS Disorders.
ACS Med Chem Lett 16: 196-197 (0)
Icahn School of Medicine at Mount Sinai
Novel Triazine Derivatives as NLRP3 Inhibitors for Treating Asthma or COPD.
ACS Med Chem Lett 16: 200-201 (0)
Smith, Gambrell & Russell
Receptor-Interacting Protein Kinase 1 (RIPK1) Inhibitors as Potential Treatment for Several Inflammatory and Neurodegenerative Diseases.
ACS Med Chem Lett 16: 204-206 (0)
PI Health Sciences
AMP-Activated Protein Kinase Activators as Therapeutic Targets To Treat Heart Failure and Diseases That Can Benefit from Improved Muscular Performance.
ACS Med Chem Lett 16: 207-209 (0)
PI Health Sciences
Discovery of First-in-Class BAZ2A/B and BAZ2B-Selective Degraders.
ACS Med Chem Lett 16: 234-240 (0)
University of Zurich
Carboxamide-Bearing Panobinostat Analogues Designed To Interact with E103-D104 at the Cavity Opening of Class I HDAC Isoforms.
ACS Med Chem Lett 16: 250-257 (0)
The University of Sydney
Exploring Arylidene-Indolinone Ligands of Autophagy Proteins LC3B and GABARAP.
ACS Med Chem Lett 16: 271-277 (0)
Tufts University
Discovery of Novel pH-Sensitive μ-Opioid Receptor Agonists as Potent Analgesics with Reduced Side Effects.
ACS Med Chem Lett 16: 285-293 (0)
Hubei University of Medicine
Design, Synthesis, and Biological Evaluation of Chiral-Proline Derivatives as Novel HSP90 Inhibitors.
ACS Med Chem Lett 16: 301-310 (0)
Dezhou University
Identification of Phosphodiesterase-7 Inhibitors with Spiro[[1,3]oxazolo[5,4-f]quinazoline-9,1'-cyclohexan]-7-one Scaffold for the Treatment of Chronic Fatigue.
ACS Med Chem Lett 16: 356-357 (0)
Emory University
Novel Pyrimidinyl Sulfonamide Derivatives as GPR17 Modulators.
ACS Med Chem Lett 16: 361-362 (0)
Emory University
Novel Cyclic Peptides Inhibiting Tumor Necrosis Factor Receptor 1 Activity.
ACS Med Chem Lett 16: 363-365 (0)
Emory University
Novel 5,6-Fused and 6,6-Fused Bicyclic Compounds as 15-Prostaglandin Dehydrogenase Modulators.
ACS Med Chem Lett 16: 366-367 (0)
Emory University
Identification of Indazole- and Azaindazole-Substituted Cyclopentapyrroles as G2019S Leucine-Rich Repeat Kinase 2 Inhibitors for the Treatment of CNS Disorders.
ACS Med Chem Lett 16: 368-370 (0)
Emory University
Is a Fungal Apocalypse Inevitable or Just a Hallucination? An Overview of the Antifungal Armamentarium Used in the Fight against Pathogenic Fungi.
ACS Med Chem Lett 16: 379-387 (0)
Charles Sturt University
Peripherally Restricted Fused Heterocyclic Peptidomimetic Multifunctional Opioid Agonists as Novel, Potent Analgesics.
ACS Med Chem Lett 16: 388-396 (0)
University of Florida
Derivatives of Aristoquinoline Accessed through a Ritter-like Reaction.
ACS Med Chem Lett 16: 406-409 (0)
University of Illinois Chicago
A Hybrid Energy-Based and AI-Based Screening Approach for the Discovery of Novel Inhibitors of AXL.
ACS Med Chem Lett 16: 410-419 (0)
Hangzhou Medical College
Exploiting Solvent Exposed Salt-Bridge Interactions for the Discovery of Potent Inhibitors of SOS1 Using Free-Energy Perturbation Simulations.
ACS Med Chem Lett 16: 444-453 (0)
Schrodinger, Inc.
Discovery of HMPL-306 (Ranosidenib), a New Potent and Selective Dual Inhibitor of Mutant IDH1 and 2 in Clinical Development for Cancer Treatment.
ACS Med Chem Lett 16: 454-463 (0)
HUTCHMED Limited
Thiosulfonate-Based Targeted Covalent Cruzipain Inhibitors with Enhanced Bioactivity Translation for Antichagasic Therapy.
ACS Med Chem Lett 16: 464-474 (0)
Universidad Nacional de Cordoba (FCQ-UNC)
In-Silico Screening-Based Discovery of New Natural eEF2K Inhibitors with Neuritogenic Activity.
ACS Med Chem Lett 16: 475-482 (0)
Jinan University
Structural Studies of the Dopamine D4 Receptor Antagonist Sonepiprazole as an Inhibitor of Human Carbonic Anhydrases.
ACS Med Chem Lett 16: 483-486 (0)
University of Florence
Development of Ethyl-Hydrazide-Based Selective Histone Deacetylase 6 (HDAC6) PROTACs.
ACS Med Chem Lett 16: 487-495 (0)
University of Bonn
Novel 6-Aryl isoindolin-1-one Derivatives as Negative Allosteric Modulators of Metabotropic Glutamate Receptor 2.
ACS Med Chem Lett 16: 510-511 (0)
Emory University
6-Aryl Isoindolin-1-ones: Novel mGluR2 Negative Allosteric Modulators.
ACS Med Chem Lett 16: 512-513 (0)
Emory University
Integrated Advancements in Neuroplasticity, Psychedelic Therapeutics, and AI-Driven Innovations for Precision Medicine.
ACS Med Chem Lett 16: 520-522 (0)
Usona Institute
Targeting Oncogenic Pathways: Advances in KRAS, CDK, EGFR, and PROTAC-Based Therapies.
ACS Med Chem Lett 16: 523-525 (0)
Usona Institute
Novel PARP7 Inhibitors for Treating Cancer.
ACS Med Chem Lett 16: 526-527 (0)
Smith, Gambrell & Russell
1,6-Naphthridine Compounds as SMARCA2 Inhibitors for Treating Non-small Cell Lung Cancer.
ACS Med Chem Lett 16: 528-529 (0)
Smith, Gambrell & Russell
Novel Cyclic Peptides as Interleukin-23 Inhibitor for Treating Inflammatory Disorders.
ACS Med Chem Lett 16: 532-533 (0)
Emory University
Novel Compounds as NLRP3 Inhibitors for Treating Asthma or COPD.
ACS Med Chem Lett 16: 538-539 (0)
Smith, Gambrell & Russell
Novel Piperidinylpyridinylcarbonitrile Derivatives as QPCT and QPCTL Inhibitors for Treating Cancer.
ACS Med Chem Lett 16: 540-541 (0)
Smith, Gambrell & Russell
Design, Synthesis, and Evaluation of a New Fluorescent Ligand for the M2 Muscarinic Acetylcholine Receptor.
ACS Med Chem Lett 16: 552-559 (0)
HUN-REN Research Centre for Natural Sciences
Synthesis and Evaluation of Thiazolidinone-Isatin Hybrids for Selective Inhibition of Cancer-Related Carbonic Anhydrases.
ACS Med Chem Lett 16: 560-566 (0)
University of Cagliari
Discovery of Novel DDR1 Inhibitors through a Hybrid Virtual Screening Pipeline, Biological Evaluation and Molecular Dynamics Simulations.
ACS Med Chem Lett 16: 602-610 (0)
Tongde Hospital of Zhejiang Province
Novel Pyrido[3,4-d]pyrimidin-4-one and Pyrimido[5,4-d]pyrimidin-4-one Derivatives as TREM2 Agonists for Treating Parkinson's Disease.
ACS Med Chem Lett 16: 715-716 (0)
Smith, Gambrell & Russell
Novel Azaindole Compounds as Phosphodiesterase 4B Inhibitors for Treating Immune-Inflammatory Diseases or Disorders.
ACS Med Chem Lett 16: 717-718 (0)
Emory University
Novel 2-Pyrrolidone Derivatives as Negative Allosteric Modulators of GluN2B-Containing NMDA Receptors.
ACS Med Chem Lett 16: 719-720 (0)
Emory University
Novel Heterocyclic Pyrimidine Derivatives as GSK3α Inhibitors.
ACS Med Chem Lett 16: 721-723 (0)
Emory University
Novel Tricyclic Compounds as GSK3 Inhibitors.
ACS Med Chem Lett 16: 724-727 (0)
Emory University
Novel Emopamil-Binding Protein Inhibitors for Treating Multiple Sclerosis.
ACS Med Chem Lett 16: 730-731 (0)
Smith, Gambrell & Russell
Novel Substituted Cyclic Compounds as SLC6A19 Inhibitors for Treating Phenylketonuria and Other Amino Acidurias.
ACS Med Chem Lett 16: 734-735 (0)
Smith, Gambrell & Russell
Targeting KRAS G12D Mutations: Advances in Small Molecule Inhibitors and PROTAC Technology.
ACS Med Chem Lett 16: 746-747 (0)
Usona Institute
Novel Sulfonamide Derivatives as Nav1.5 Sodium Channel Blockers for Treating Atrial Fibrillation.
ACS Med Chem Lett 16: 748-749 (0)
Emory University
Novel Isoxazolidines Derivatives as RIPK1 Inhibitors for Treating Neurodegenerative Diseases.
ACS Med Chem Lett 16: 754-755 (0)
Smith, Gambrell & Russell
Novel Compounds as NLRP3 Inhibitors for Treating Asthma or COPD.
ACS Med Chem Lett 16: 760-761 (0)
Smith, Gambrell & Russell
Novel Piperidine Substituted Pyrazolopyrimidine Derivatives as SGK1 Inhibitors for Treating Cardiovascular Diseases.
ACS Med Chem Lett 16: 762-763 (0)
Smith, Gambrell & Russell
Novel Spirocyclic WRN Helicase Inhibitors for Treating Cancer.
ACS Med Chem Lett 16: 764-765 (0)
Smith, Gambrell & Russell LLP
Macrocyclization: Enhancing Drug-like Properties of Discoidin Domain Receptor Kinase Inhibitors.
ACS Med Chem Lett 16: 784-789 (0)
Chiesi Farmaceutici
Discovery of Thieno[3,2-b]pyridine-5-carboxamide and 2,3-Difluorobenzamide Negative Allosteric Modulators of Metabotropic Glutamate Receptor Subtype 5.
ACS Med Chem Lett 16: 865-874 (0)
Vanderbilt University
IRAK1/4/pan-FLT3 Kinase Inhibitors with Reduced hERG Block as Treatments for Acute Myeloid Leukemia.
ACS Med Chem Lett 16: 887-895 (0)
National Center for Advancing Translational Sciences